ASCO 2025 Archives - Medical Conferences

Home > Oncology > ASCO 2025

American Society of Clinical Oncology
30 May–03 June 2025
Chicago, USA

Double the impact with less BCG: mitomycin combo maintains efficacy in NMIBC

Presented By

Prof. Dickon Hayne, UWA Medical School, Perth, Australia

Trial

Phase 3, BCGMM, ANZUP 1301

Conference

ASCO 2025

Type

News article

3 June 2025 15:19

BREAKWATER makes waves in BRAF V600E-mutant mCRC treatment

Presented By

Dr Elena Élez, Vall d’Hebron Institute of Oncology, Barcelona, Spain

Trial

Phase 3, BREAKWATER

Conference

ASCO 2025

Type

News article

2 June 2025 13:47

Online First

A chemo-free second-line option for MET-amplified NSCLC

Presented By

Dr Shun Lu, Shanghai Chest Hospital, China

Trial

Phase 3, SACHI

Conference

ASCO 2025

Type

News article

5 June 2025 13:26

Nivolumab addition sets the first new post-operative standard for head-and-neck cancer in two decades

Presented By

Prof. Jean Bourhis, Lausanne University Hospital, Switzerland

Trial

Phase 3, NIVOPOSTOP

Conference

ASCO 2025

Type

News article

5 June 2025 13:24

Anlotinib prolongs PFS in glioblastoma

Presented By

Dr Yuanyuan Chen, Sun Yat-sen University Cancer Center, China

Trial

Phase 2

Conference

ASCO 2025

Type

News article

5 June 2025 13:21

Timing of cytoreductive surgery does not impact OS in ovarian cancer

Presented By

Dr Sven Mahner, LMU University Hospital Munich, Germany

Trial

Phase 3, TRUST

Conference

ASCO 2025

Type

News article

5 June 2025 13:19

No added benefit of relatlimab in the adjuvant melanoma setting

Presented By

Dr Georgina Long, Melanoma Institute Australia

Trial

Phase 3, RELATIVITY-098

Conference

ASCO 2025

Type

News article

5 June 2025 13:16

Benmelstobart-anlotinib combination superior to pembrolizumab in advanced NSCLC

Presented By

Dr Baohui Han, Shanghai Chest Hospital, China

Trial

Phase 3, CAMPASS

Conference

ASCO 2025

Type

News article

4 June 2025 11:32

Rusfertide improves symptoms and quality-of-life in polycythaemia vera

Presented By

Dr Andrew Kuykendall, Moffitt Cancer Center, FL, USA

Trial

Phase 3, VERIFY

Conference

ASCO 2025

Type

News article

4 June 2025 11:30

Anlotinib non-inferior to bevacizumab in first-line treatment of mCRC

Presented By

Dr Ke-Feng Ding, Zhejiang University School of Medicine, Hangzhou, China

Trial

Phase 3, ANCHOR

Conference

ASCO 2025

Type

News article

3 June 2025 15:22

ATOMIC trial establishes new standard for adjuvant treatment in dMMR stage 3 colon cancer

Presented By

Prof. Frank Sinicrope, Mayo Clinic, Rochester, MN, USA

Trial

Phase 3, ATOMIC

Conference

ASCO 2025

Type

News article

3 June 2025 15:20

Double the impact with less BCG: mitomycin combo maintains efficacy in NMIBC

Presented By

Prof. Dickon Hayne, UWA Medical School, Perth, Australia

Trial

Phase 3, BCGMM, ANZUP 1301

Conference

ASCO 2025

Type

News article

3 June 2025 15:19

TTFields therapy shows survival benefit in unresectable pancreatic cancer

Presented By

Dr Vincent Picozzi, Virginia Mason Medical Centre, Seattle, WA, USA

Trial

Phase 3, PANOVA-3

Conference

ASCO 2025

Type

News article

2 June 2025 13:54

Sacituzumab govitecan plus pembrolizumab outperforms chemotherapy in PD-L1+ metastatic TNBC

Presented By

Dr Sara M. Tolaney, Dana-Farber Cancer Institute and Harvard Medical School, Boston, MA, USA

Trial

Phase 3, ASCENT-04, KEYNOTE-D19

Conference

ASCO 2025

Type

News article

2 June 2025 13:53

Vepdegestrant outperforms fulvestrant in ESR1-mutant aBC

Presented By

Dr Erika Hamilton, Sarah Cannon Research Institute, Nashville, TN, USA

Trial

Phase 3, VERITAC-2

Conference

ASCO 2025

Type

News article

2 June 2025 13:51

DESTINY delivered: Trastuzumab deruxtecan extends survival in HER2-positive gastric cancer

Presented By

Dr Kohei Shitara, National Cancer Centre Hospital East, Kashiwa, Japan

Trial

Phase 3, DESTINY-Gastric04

Conference

ASCO 2025

Type

News article

2 June 2025 13:49

BREAKWATER makes waves in BRAF V600E-mutant mCRC treatment

Presented By

Dr Elena Élez, Vall d’Hebron Institute of Oncology, Barcelona, Spain

Trial

Phase 3, BREAKWATER

Conference

ASCO 2025

Type

News article

2 June 2025 13:47

Medical Conferences

ASCO 2025

Featured articles

Double the impact with less BCG: mitomycin combo maintains efficacy in NMIBC

BREAKWATER makes waves in BRAF V600E-mutant mCRC treatment

CONTENTS

Online First

A chemo-free second-line option for MET-amplified NSCLC

Nivolumab addition sets the first new post-operative standard for head-and-neck cancer in two decades

Anlotinib prolongs PFS in glioblastoma

Timing of cytoreductive surgery does not impact OS in ovarian cancer

No added benefit of relatlimab in the adjuvant melanoma setting

Benmelstobart-anlotinib combination superior to pembrolizumab in advanced NSCLC

Rusfertide improves symptoms and quality-of-life in polycythaemia vera

Anlotinib non-inferior to bevacizumab in first-line treatment of mCRC

ATOMIC trial establishes new standard for adjuvant treatment in dMMR stage 3 colon cancer

Double the impact with less BCG: mitomycin combo maintains efficacy in NMIBC

TTFields therapy shows survival benefit in unresectable pancreatic cancer

Sacituzumab govitecan plus pembrolizumab outperforms chemotherapy in PD-L1+ metastatic TNBC

Vepdegestrant outperforms fulvestrant in ESR1-mutant aBC

DESTINY delivered: Trastuzumab deruxtecan extends survival in HER2-positive gastric cancer

BREAKWATER makes waves in BRAF V600E-mutant mCRC treatment